

Enigmatters

the newsletter of Enigma Diagnostics

Issue 1


Winter 2009

Enigma Launches ML “Mini-Laboratory”

The Enigma ML was proudly showcased for the first time at the Abu Dhabi Medical Congress 2009 in October. The event was opened by his Excellency Zaid Al Siksek CEO of the Health Authority. Enigma’s stand attracted professionals working across the regions’ Primary Healthcare, Emergency, Patient Safety and Rehabilitation sectors.

The congress presented the latest in healthcare technology and innovation and with Porton Group working alongside Enigma at the stand, visitors were able to view the first Enigma ML system which was met with widespread acclaim from supporters.

The Enigma ML road show continued in November at Medica in Dusseldorf, the largest clinical exhibition in Europe. As part of the UK Government’s Trade and Investment initiative, the ML was met with universal approval, not least by Lord Darzi (below) who specifically



L-R Dr. Ian George, Business Development Director Enigma, Harvey Boulter, CEO Porton Group, John McKinley, Chairman & CEO Enigma, Gavin Furber-Smith Porton Group, Sharlene Jackson, Porton Group.

visited Enigma’s stand to meet with John McKinley and see the ML system. His supportive comments on the ML’s immediate relevance to hospitals and the new concept of ‘polyclinics’ highlights the need for this unique system in the UK and overseas.

The new Enigma ML also drew a huge amount of interest from many of the attending trade visitors and media and a substantial amount of investment and business opportunities were gained, proving that the ML will be a favourite amongst medical professionals and a leader in its field.



The Enigma ML system



The Chairman (right) presents the ML to an enthralled Lord Darzi

In this issue:

| | |
|-----------------------------|---|
| Enigma ML launched | 1 |
| Manufacturing line at TECAN | 2 |
| Senior Recruitment | 2 |
| Expanding Patent Portfolio | 3 |
| New Oxford office | 3 |
| Chairman’s message | 4 |

Newsflash:

- Enigma’s first subsidiary, Enigma Diagnostics Inc., was incorporated in November
- Enigma to attend Arab Health 2010 conference in Dubai 25-28 January 2010
- Enigma to attend XII International Symposium on Respiratory Viral Infections in Taipei 11-14 March 2010

ML's on the first Production Line at TECAN... a credit to the Enigma Team

The picture of success. Enigma has established its first ML production line at TECAN (Switzerland) producing ML's for demonstrations and trials from January 2010. The Enigma ML's prototype development has been completed 9 months early. It is testimony to the dedicated hard work and professionalism of our Enigma team over the past 18 months that we are now able to deliver this unique system in 2010 and effect a paradigm shift in healthcare testing to developed and developing healthcare economies.

The first ML's off the production line at TECAN



Expansion of the US and European Executive Management Team

As Enigma moves quickly towards regulatory driven manufacturing and commercialisation of the ML system in 2010, the need for expanded expertise increases. Recent senior appointments across finance, operations and regulatory will provide Enigma with the necessary additional expertise to deliver our objectives for 2010 and beyond.



Dr. Jorge Garces

In the US Dr. Jorge Garces joins as President and CEO, USA. Formerly, Vice President of R&D and Site Operations Manager at Hologic, Jorge brings a wealth of experience in the molecular diagnostics business, including groundbreaking HPV and Cystic Fibrosis products which attained FDA approval.

Greg Hamilton joins as Chief Operating Officer and Chief Financial Officer, USA. Previously, also



Greg Hamilton

from Hologic where he held the position of Vice President of Operations, Planning and Analysis for their women's healthcare products. Formerly, Vice President of Finance and Operations at Third Wave, Greg was instrumental in the sale of the company to Hologic for \$582million in 2008.

In Europe, Nick Williams joins as Chief Financial Officer with over 15 years experience in his field. Formerly of Alchemy Partners, Nick's business strategies achieved high growth annual return to investors and a secondary exit process generated over £100million to shareholders. Nick's central role in the management team of contact lens company Biocompatibles saw its sale to Cooper Companies for over £110million.



Nick Williams

Darren Hall joins as Chief Operating Officer. Formerly Managing Director of Singapore

based Clearlab International, he brings extensive expertise in bringing new products to market and in developing successful operational and supply chain strategies. Darren has previously held board positions at Graseby Plc, Smith Industries and Biocompatibles, where he was involved in a number of acquisitions and divestments. He was also a member of the successful Biocompatible management team alongside Nick.



Darren Hall

2010 will see additional appointments across Enigma's core Regulatory and Sales and Marketing activities. Complementing the current strengths of Enigma's management, the combined team represents the broadest skill base ensuring fast-track building of Enigma's infrastructure to support rapid commercialisation across global markets.

Patent portfolio expansion and out-licensing

One of Enigma's core strengths continues to be its Intellectual



Property portfolio which protects our current and future products. Additional patent filings contribute to a portfolio of over 300 filed and 80 granted global patents providing both protection and the opportunity for an out-licensing programme to

third parties infringers and to countries wishing to use a complete rt-PCR molecular capability. 2010 will therefore see Enigma's new licensing programme in the USA and Europe as well as within the ASEAN region.

Enigma's new Oxford location

At the end of August Enigma opened its second UK location at Milton Park, Oxford. Milton Park is one of Europe's largest and fastest growing business parks and with easy access to all major motorways and Heathrow makes it the perfect choice for Enigma's expanding operations. Currently housing the growing Design &

Engineering Department team, the offices will expand across corporate, IP, commercial and finance activities in early 2010.



Enigma's Oxford Office

"Milton Park, in the heart of the Oxford-Cambridge-London science hub, the perfect environment for Enigma's rapidly expanding business"

E: info@enigmadiagnostics.com
T: +44 (0)1980 590131

Wishing you a joyous
Christmas Season
and a successful 2010
from all the team at
Enigma Diagnostics Ltd

enigmadiagnostics
secure rapid results
www.enigmadiagnostics.com



This first Newsletter and the near end of 2009 provides a rare opportunity to review 2009 and what 2010 and beyond will bring to Enigma. 2009 has delivered the ML—a first of its kind and the first of a range of Enigma instrument systems which will change the face of patient diagnosis and treatment in the future. There are very few healthcare companies in the world today which encompass Enigma's breadth and depth of technologies and product offering. Uniquely - and this is where I believe Enigma transcends normal company goals and ambitions, we have "disruptive technology" which offers a paradigm shift in healthcare diagnosis and treatment to patients and developing healthcare economies.

With our dedicated staff and development partners producing the unrivalled ML system, success for Enigma in 2010 is a certainty. We have embarked on an ambitious roll-out for the ML system with global infrastructural support systems and from 2010 we will deliver commensurate returns to our longstanding investors and stakeholder supporters. In addition, we will develop the next generation of technologies and systems to support our vision.

I would like to take this opportunity to thank everyone who has supported Enigma in achieving this unique position and leave you with our vision for our future:

- We will be a leading Healthcare Solutions company offering innovative diagnostic systems at point-of-need
- We will be the leader in global decentralised testing

Wishing you a very enjoyable festive season.

John McKinley


Chairman & CEO

Enigma Diagnostics Limited
Milton Park Innovation Centre
99 Milton Park
Abingdon, Oxfordshire.
OX14 4RY

Phone: 01235 854074
Fax: 01235 854089

Enigma Diagnostics Limited
224 Tetricus Science Park
DSTL Porton Down
Salisbury, Wiltshire.
SP4 0JQ

Phone: 01980 590131
Fax: 01980 590132



www.enigmadiagnostics.com